Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Phase Ⅱb Clinical Trial to Evaluate the Efficacy and Safety of the KPCXM18 Injection at Different Doses in The Treatment of Acute Ischemic Stroke

NCT07279493 is registered in ClinicalTrials.gov with Kunming Pharmaceuticals, Inc. as lead sponsor.

NCT NCT07279493
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07279493 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Phase Ⅱb Clinical Trial to Evaluate the Efficacy and Safety of the KPCXM18 Injection at Different Doses in The Treatment of Acute Ischemic Stroke
Lead sponsor
Kunming Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
November 22, 2025
Completion date
October 18, 2026
Enrollment
300 (estimated)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischemic stroke